An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers
- PMID: 22476196
- PMCID: PMC3314445
- DOI: 10.1172/JCI57256
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers
Abstract
Defective brain insulin signaling has been suggested to contribute to the cognitive deficits in patients with Alzheimer's disease (AD). Although a connection between AD and diabetes has been suggested, a major unknown is the mechanism(s) by which insulin resistance in the brain arises in individuals with AD. Here, we show that serine phosphorylation of IRS-1 (IRS-1pSer) is common to both diseases. Brain tissue from humans with AD had elevated levels of IRS-1pSer and activated JNK, analogous to what occurs in peripheral tissue in patients with diabetes. We found that amyloid-β peptide (Aβ) oligomers, synaptotoxins that accumulate in the brains of AD patients, activated the JNK/TNF-α pathway, induced IRS-1 phosphorylation at multiple serine residues, and inhibited physiological IRS-1pTyr in mature cultured hippocampal neurons. Impaired IRS-1 signaling was also present in the hippocampi of Tg mice with a brain condition that models AD. Importantly, intracerebroventricular injection of Aβ oligomers triggered hippocampal IRS-1pSer and JNK activation in cynomolgus monkeys. The oligomer-induced neuronal pathologies observed in vitro, including impaired axonal transport, were prevented by exposure to exendin-4 (exenatide), an anti-diabetes agent. In Tg mice, exendin-4 decreased levels of hippocampal IRS-1pSer and activated JNK and improved behavioral measures of cognition. By establishing molecular links between the dysregulated insulin signaling in AD and diabetes, our results open avenues for the investigation of new therapeutics in AD.
Figures









Comment in
-
Alzheimer’s disease: the new promise.J Clin Invest. 2012 Apr;122(4):1191. doi: 10.1172/jci62745. J Clin Invest. 2012. PMID: 22754953 Free PMC article.
Similar articles
-
Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin.J Neurosci. 2009 Jul 15;29(28):9078-89. doi: 10.1523/JNEUROSCI.1071-09.2009. J Neurosci. 2009. PMID: 19605645 Free PMC article.
-
(-)-Epigallocatechin-3-gallate alleviates spatial memory impairment in APP/PS1 mice by restoring IRS-1 signaling defects in the hippocampus.Mol Cell Biochem. 2013 Aug;380(1-2):211-8. doi: 10.1007/s11010-013-1675-x. Epub 2013 May 10. Mol Cell Biochem. 2013. PMID: 23660953
-
TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys.Cell Metab. 2013 Dec 3;18(6):831-43. doi: 10.1016/j.cmet.2013.11.002. Cell Metab. 2013. PMID: 24315369
-
The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications.CNS Neurol Disord Drug Targets. 2014 Mar;13(2):322-37. doi: 10.2174/18715273113126660141. CNS Neurol Disord Drug Targets. 2014. PMID: 24059318 Review.
-
An update on potential links between type 2 diabetes mellitus and Alzheimer's disease.Mol Biol Rep. 2020 Aug;47(8):6347-6356. doi: 10.1007/s11033-020-05693-z. Epub 2020 Aug 1. Mol Biol Rep. 2020. PMID: 32740795 Review.
Cited by
-
The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors.Diabetes Metab Syndr Obes. 2022 Aug 22;15:2583-2597. doi: 10.2147/DMSO.S375559. eCollection 2022. Diabetes Metab Syndr Obes. 2022. PMID: 36035518 Free PMC article. Review.
-
Alzheimer’s disease: the new promise.J Clin Invest. 2012 Apr;122(4):1191. doi: 10.1172/jci62745. J Clin Invest. 2012. PMID: 22754953 Free PMC article.
-
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease.Front Endocrinol (Lausanne). 2022 Nov 17;13:1033479. doi: 10.3389/fendo.2022.1033479. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36465634 Free PMC article. Review.
-
Adaptive immune cells shape obesity-associated type 2 diabetes mellitus and less prominent comorbidities.Nat Rev Endocrinol. 2022 Jan;18(1):23-42. doi: 10.1038/s41574-021-00575-1. Epub 2021 Oct 26. Nat Rev Endocrinol. 2022. PMID: 34703027 Free PMC article. Review.
-
Deterioration of plasticity and metabolic homeostasis in the brain of the UCD-T2DM rat model of naturally occurring type-2 diabetes.Biochim Biophys Acta. 2014 Sep;1842(9):1313-23. doi: 10.1016/j.bbadis.2014.05.007. Epub 2014 May 16. Biochim Biophys Acta. 2014. PMID: 24840661 Free PMC article.
References
-
- White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 2002;283(3):E413–E422. - PubMed
-
- Craft S. Insulin resistance and Alzheimer’s disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4(2):147–152. - PubMed
-
- Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31(2):224–243. doi: 10.1016/j.neurobiolaging.2008.04.002. - DOI - PubMed
-
- Steen E, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease — is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63–80. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous